Viewing Study NCT05576571



Ignite Creation Date: 2024-05-06 @ 6:11 PM
Last Modification Date: 2024-10-26 @ 2:43 PM
Study NCT ID: NCT05576571
Status: UNKNOWN
Last Update Posted: 2022-10-17
First Post: 2022-10-06

Brief Title: The Utility of Cell-free Methylation Markers in Blood for Hepatocellular Carcinoma
Sponsor: National Taiwan University Hospital
Organization: National Taiwan University Hospital

Study Overview

Official Title: The Utility of Cell-free Methylation Markers in Blood for the Prognosis Prediction of Locoregional Treatment for Hepatocellular Carcinoma
Status: UNKNOWN
Status Verified Date: 2022-06
Last Known Status: ACTIVE_NOT_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Patients with liver cancer expected to undergo radiofrequency ablation or transvascular embolization Relevant tumor markers AFP and methylation analysis were performed The two data are then counted and compared
Detailed Description: The subjects of this study were patients who were diagnosed with liver cancer by physicians based on AASLD clinical criteria or pathological biopsy

Patients are those who received radiofrequency ablation or transvascular embolization in National Taiwan University Hospital Which excludes weakness and inability to cooperate Patients with blood test under the condition of fully informed consent complete blood test related tumor indicators AFP and methylation analysis The two data are then counted Compare

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None